14 Results for "

polymorphonuclear cell

" in MedChemExpress (MCE) Product Catalog:
Products (14)

14 Results for "polymorphonuclear cell" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-P0172
CAS No.: 1337878-62-2
Target:  

CXCR

ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P0172A
Target:  

CXCR

ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-114041
CAS No.: 552830-51-0
Purity:  95.30%
Synonyms: RvE1
Resolvin E1 (RvE1), a potent endogenous pro-resolving mediator of inflammation, is derived from omega-3 fatty acid eicosapentaenoic acid (EPA). Resolvin E1 is endogenously biosynthesized from EPA in the presence of Aspirin during the spontaneous resolution phase of acute inflammation, where specific cell-cell interactions occur. Resolvin E1 possesses unique counterregulatory actions that inhibit polymorphonuclear leukocyte (PMN) transendothelial migration. Resolvin E1 also acts as a potent inhibitor of leukocyte infiltration, dendritic cell migration, and IL-12 production .
loading...
    loading...
Cat. No.: HY-N3945
CAS No.: 475-81-0
Synonyms: O,O-Dimethylisoboldine; S-(+)-Glaucine; NSC 34396
Glaucine (O,O-Dimethylisoboldine) is an alkaloid extracted from Glaucium flavum that possesses various activities, including cough relief, bronchodilation, anti-inflammatory effects, analgesia, antipyretic properties, and anticancer effects. Glaucine acts as a selective and orally active inhibitor of phosphodiesterase 4 (PDE4), with a Ki of 3.4 µM in human bronchial tissues and polymorphonuclear leukocytes. Glaucine induces relaxation of human isolated bronchi by antagonizing calcium channels. Additionally, Glaucine inhibits the activation of NF-κB, leading to a reduction in the expression of the MMP-9 gene, thereby suppressing the migration and invasion of breast cancer cells. Therefore, Glaucine holds potential for research in asthma and breast cancer .
loading...
    loading...
Cat. No.: HY-12927
CAS No.: 1240494-13-6
Purity:  99.88%
Target:  

CXCR

Research Areas:  

Inflammation/Immunology

SX-517 is a dual CXCR2/1 antagonist, containing boronic acid. SX-517 inhibits CXCL1-induced Ca 2+ flux (IC50=38 nM), and antagonizes CXCL8-induced [(35)S]GTPγS binding (IC50=60 nM) and ERK1/2 phosphorylation. SX-517 has significant ability for inflammation suppression, in both humanized polymorphonuclear (PMN) cells and in murine model .
loading...
    loading...
Cat. No.: HY-114041S
Synonyms: RvE1-d4
Resolvin E1-d4 (RvE1-d4) is deuterium labeled Resolvin E1. Resolvin E1 (RvE1), a potent endogenous pro-resolving mediator of inflammation, is derived from omega-3 fatty acid eicosapentaenoic acid (EPA). Resolvin E1 is endogenously biosynthesized from EPA in the presence of Aspirin during the spontaneous resolution phase of acute inflammation, where specific cell-cell interactions occur. Resolvin E1 possesses unique counterregulatory actions that inhibit polymorphonuclear leukocyte (PMN) transendothelial migration. Resolvin E1 also acts as a potent inhibitor of leukocyte infiltration, dendritic cell migration, and IL-12 production .
loading...
    loading...
Cat. No.: HY-120314
CAS No.: 144576-10-3
GEA 3162 is an orally active compound that acts as a NO/ONOO⁻ donor. GEA 3162 significantly inhibits the activation of human polymorphonuclear leukocytes (PMNs) through the cGMP pathway, inhibits the release of inflammatory mediators, and exerts anti-inflammatory and protective effects. GEA 3162 induces apoptosis of neutrophils and bone marrow cells by activating caspase-2/3/8/9 through the ONOO⁻ pathway. GEA 3162 has a bidirectional effect in the rat gastric ulcer model: at low doses, it significantly reduces gastric mucosal damage, while at high doses, it aggravates the ulcer area. GEA 3162 can be used for research on inflammatory conditions such as gastric ulcers .
loading...
    loading...
Cat. No.: HY-114041S1
CAS No.: 2714040-94-3
Synonyms: RvE1-d4-1
Resolvin E1-d4-1 is the deuterium labeled Resolvin E1. Resolvin E1 (RvE1), a potent endogenous pro-resolving mediator of inflammation, is derived from omega-3 fatty acid eicosapentaenoic acid (EPA). Resolvin E1 is endogenously biosynthesized from EPA in the presence of Aspirin during the spontaneous resolution phase of acute inflammation, where specific cell-cell interactions occur. Resolvin E1 possesses unique counterregulatory actions that inhibit polymorphonuclear leukocyte (PMN) transendothelial migration. Resolvin E1 also acts as a potent inhibitor of leukocyte infiltration, dendritic cell migration, and IL-12 production .
loading...
    loading...
Cat. No.: HY-117108
CAS No.: 39391-39-4
Nocardicin A is a monocyclic β-lactam antibiotic with broad-spectrum activity against Gram-negative bacteria. Nocardicin A inhibits bacterial cell wall synthesis and synergistically stimulates the phagocytic and bactericidal functions of polymorphonuclear leukocytes (PMN). Nocardicin A can be used in research on Gram-negative bacterial infections .
loading...
    loading...
Cat. No.: HY-113484
CAS No.: 80445-66-5
Synonyms: LTB5
Target:  

Leukotriene Receptor

Research Areas:  

Cancer

Leukotriene B5 (LTB5) is a leukotriene with diverse biological activities. It is a metabolite of eicosapentaenoic acid formed through the 5-lipoxygenase (5-LO) pathway. LTB5 increases contraction of bullfrog lung strips ex vivo in a concentration-dependent manner. In vivo, LTB5 (100 nM) reduces tumor volume in mice injected with Tm1 murine melanoma cells. LTB5 also elicits chemokinesis and lysosomal enzyme release from polymorphonuclear leukocytes (PMNLs) 20- to 30-fold less, and induces platelet aggregation 8-fold less, potently than LTB4.
loading...
    loading...
Cat. No.: HY-N14970
CAS No.: 903574-41-4
Hexacyclinol has moderate anti-Gram-positive bacteria activity, 4-40 μg/mL can inhibit the production of oxidants by polymorphonuclear neutrophils (PMNL) stimulated by zymosan. Hexacyclinol inhibits the growth of L-930 and K 562 cells with IC50s of 1.4 μg/mL and 0.4 μg/mL, respectively, and the IC50 of HeLa cells is 10 μg/mL. Hexacyclinol also has an anti-Plasmodium effect, and its IC50 for Plasmodium falciparum is 2.4 μg/mL .
loading...
    loading...
Cat. No.: HY-120314A
GEA 3162 hydrochloride is an orally active compound that acts as a NO/ONOO⁻ donor. GEA 3162 hydrochloride significantly inhibits the activation of human polymorphonuclear leukocytes (PMNs) through the cGMP pathway, inhibits the release of inflammatory mediators, and exerts anti-inflammatory and protective effects. GEA 3162 hydrochloride induces apoptosis of neutrophils and bone marrow cells by activating caspase-2/3/8/9 through the ONOO⁻ pathway. GEA 3162 hydrochloride has a bidirectional effect in the rat gastric ulcer model: at low doses, it significantly reduces gastric mucosal damage, while at high doses, it aggravates the ulcer area. GEA 3162 hydrochloride can be used for research on inflammatory conditions such as gastric ulcers .
loading...
    loading...
Cat. No.: HY-W751362
CAS No.: 14176-10-4
Cetiedil is a vasodilator and potassium channel blocker with anti-sickle cell and analgesic activities. Cetiedil increases cyclic adenosine monophosphate levels, relaxes vascular smooth muscle, and blocks the action of Bradykinin (HY-P0206). Cetiedil inhibits platelet aggregation, reduces plasma fibrinogen concentration and blood viscosity, suppresses sickling of sickle red blood cells and improves their filterability, and decreases irreversible sickle cells. Cetiedil binds to calmodulin, inhibits Ca 2+-dependent potassium permeability of erythrocyte membranes, increases sodium permeability of erythrocytes, and regulates polymorphonuclear leukocyte function. Cetiedil can be used in research related to intermittent claudication, arteriosclerosis obliterans, diabetic arteriosclerosis, Raynaud's disease, angina pectoris, and sickle cell anemia .
loading...
    loading...
Cat. No.: HY-W726101
CAS No.: 5996-06-5
Synonyms: O,O-Dimethylisoboldine hydrobromide; S-(+)-Glaucine hydrobromide; NSC 34396 hydrobromide
Glaucine hydrobromide (O,O-Dimethylisoboldine hydrobromide; S-(+)-Glaucine hydrobromide; NSC 34396 hydrobromide) is an alkaloid extracted from Glaucium flavum that possesses various activities, including cough relief, bronchodilation, anti-inflammatory effects, analgesia, antipyretic properties, and anticancer effects. Glaucine hydrobromide acts as a selective and orally active inhibitor of phosphodiesterase 4 (PDE4), with a Ki of 3.4 µM in human bronchial tissues and polymorphonuclear leukocytes. Glaucine hydrobromide induces relaxation of human isolated bronchi by antagonizing calcium channels. Additionally, Glaucine hydrobromide inhibits the activation of NF-κB, leading to a reduction in the expression of the MMP-9 gene, thereby suppressing the migration and invasion of breast cancer cells. Therefore, Glaucine hydrobromide holds potential for research in asthma and breast cancer .
loading...
    loading...
  • 1